Gensight Biologics Reaches Deal With ANSM For Opening Of Lumevoq Early Access Program In France
Refinitiv閱讀少於1分鐘
Gensight Biologics SA 
SIGHT:
GENSIGHT BIOLOGICS REACHES AGREEMENT WITH ANSM FOR OPENING OF LUMEVOQ® NAMED EARLY ACCESS PROGRAM (AAC) IN FRANCE
GENSIGHT BIOLOGICS SA - TARGETS Q3 2025 FOR FINALIZING DOSE-RANGING STUDY PROTOCOL
GENSIGHT BIOLOGICS SA - AAC PROGRAM TARGETED TO OPEN IN Q4 2025
登入或建立一個永久免費帳戶來閱讀此新聞